PeterRubinMD

Oncology • Biddeford, ME

CMO Global Oncology Associates

Join to view full profile

Dr. Rubin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rubin's full profile

Already have an account?

Office
1 Medical Center Dr
Biddeford, ME 04005
Phone+1 207-294-5800

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 1992 - 1995
University of Calgary Faculty of MedicineClass of 1988

Certifications & Licensure

NJ State Medical License 1973 - Present
IA State Medical License 2023 - 2025
ME State Medical License 2016 - 2025
NH State Medical License 2017 - 2025
NC State Medical License 1993 - 2021
NY State Medical License 2014 - 2016
WA State Medical License 1993 - 2015
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
Tesetaxel as First-line Therapy for Metastatic Breast Cancer Start of enrollment: 2010 Nov 01
Unknown status
Phase 2
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer Start of enrollment: 2011 Apr 01
Completed
Not Applicable
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer Start of enrollment: 2012 Feb 01
Completed
Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Re: Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology 2017;115(8):91...
Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani
Journal of Surgical Oncology. 2017-07-28
70 citations
Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani
Journal of Surgical Oncology. 2017-06-01
2 citations
Phase II study of lapatinib in combination with vinorelbine, as first or second-line therapy in women with HER2 overexpressing metastatic breast cancer
Helen K. Chew, Lee S. Schwartzberg, Suprith Badarinath, Peter Rubin, Grace Shumaker
Springerplus. 2014-02-22

Press Mentions

Number of Cancer Clinical Trials to Triple in Maine as NCROP Infuses $5.1M into Maine Health Cancer Care Network (MNCCN)October 7th, 2019

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member